Clinical Trial Update: Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the administration of donor-derived multi TAA-specific T cells (ADSPAM) for acute myeloid leukemia or myelodysplastic syndrome…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Donor Multi TAA-Specific T Cells (ADSPAM)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Status: ACTIVE_NOT_RECRUITING